Japan’s Matsushita To Market New Drug-Discovery System Soon
This article was originally published in PharmAsia News
Matsushita Electric Industrial plans to develop a new drug-discovery system in conjunction with Kalapsys and market it in North America and Europe. The system, commercialized by Matsushita subsidiary Panasonic Factory Solutions is capable of processing more than 1,500 compounds in a minute and is said to be easily expandable to add other functions, such as transfering compounds or mixing proteins. Matsushita and Kalypsys, a Novartis spinoff, plan to market the system in North America within a few months, with an aim for the top market share by 2010. (Click here for more - a subscription may be required
You may also be interested in...
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.
A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.